FindTrial
Sign In

To understand the changes in genes present in the DNA during Cervical Cancer progression

Translation of CpG-Methylation Biosignatures of Genes for Rapid and Sensitive Diagnostic and Prognostic Applications during Cervical Cancer Progression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/11/016296
Enrollment
600
Registered
2018-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N72- Inflammatory disease of cervix uteri

Interventions

None listed

Sponsors

Dr K Satyamoorthy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Case: Women aged between 21-65 years with pre-malignant and malignant cervical lesions are included in this study. Control: Women aged between 21-65 years without any cervical lesions or symptoms are included as control participants.

Exclusion criteria

Exclusion criteria: Case: Women who are pregnant or lactating; who have undergone hysterectomy; who are diagnosed and have already started treatment for cervical lesions and malignancies are excluded from the study. Control: Women who are pregnant or lactating; who have undergone hysterectomy; who are diagnosed and have already started treatment for cervical lesions and malignancies are excluded from the study.

Design outcomes

Primary

MeasureTime frame
A visual based cervical cancer detection systemTimepoint: 5 years—

Secondary

MeasureTime frame
Identification of DNA methylation regulated genes in Cervical CancerTimepoint: 5 years—

Countries

India

Contacts

Public ContactDr Anshul Singh

School of Life Sciences, Manipal

spbhat81@gmail.com9886741415

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026